Pharmacological maintenance of protein homeostasis could postpone age-related disease

Silvestre Alavez1, Gordon J Lithgow

  • 1Buck Institute for Research on Aging, Novato, CA 94945, USA. salavez@buckinstitute.org

Aging Cell
|January 10, 2012
PubMed

Insights

Small molecules can extend lifespan and improve healthspan by enhancing protein homeostasis. Research in Caenorhabditis elegans shows these interventions may prevent age-related diseases.

Area of Science:

  • Gerontology and molecular biology
  • Investigating the biological mechanisms of aging and longevity

Background:

  • Aging is a major risk factor for chronic diseases.
  • Protein aggregation is linked to several age-related conditions.
  • Maintaining protein homeostasis is crucial for longevity.

Purpose of the Study:

  • Review small molecule interventions targeting aging.
  • Focus on compounds enhancing protein homeostasis in C. elegans.
  • Evaluate potential for preventing age-related diseases.

Main Methods:

  • Analysis of published studies on small molecule screens for aging interventions.
  • Review of research identifying chemicals that maintain protein homeostasis in C. elegans.
  • Synthesis of findings on lifespan extension and healthspan improvement.

Main Results:

  • Pharmacological lifespan extension demonstrated in mice.
  • Several chemicals identified in C. elegans that enhance protein homeostasis and extend lifespan.
  • These interventions show promise for improving healthspan.

Conclusions:

  • Enhancing protein homeostasis is a viable strategy for promoting longevity.
  • Small molecules targeting protein homeostasis may prevent age-related diseases.
  • Further research in C. elegans can inform human healthspan interventions.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...